Overview
- A multicenter study published in Nature Medicine on Wednesday found PANXEON identified about 86 to 87 percent of stage I and II pancreatic ductal adenocarcinomas in 1,757 plasma samples from 1,649 people across the United States, Europe and Asia.
- The test combines a 13‑microRNA signature with the tumor marker CA19‑9 and an XGBoost machine‑learning model, producing a single risk score; the microRNA signature alone had an AUROC of 88.6% and 83.8% sensitivity for early disease.
- PANXEON also detected high‑grade dysplasia in pancreatic cysts with roughly 64.3% sensitivity and showed that miRNA levels fall with treatment and rise before recurrence in a small monitoring cohort.
- Performance varied by risk group with low false positives in low‑risk controls (about 3%) but higher false positives in high‑risk controls (about 15–16%), and the authors warn a positive result should prompt further evaluation rather than immediate surgery.
- Investigators say the next step is prospective, longitudinal trials in intended surveillance populations to show that molecular testing leads to more resectable cancers, fewer unnecessary procedures, and better patient outcomes.